Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Terminated

Irreversible Electroporation for Inoperable Hepatic and Pancreatic Malignancy

Outcome
Stopped earlypoor case accural (Other)
Phase
No phase (not a drug trial)
Status
Terminated
Study type
Interventional
Start
22 July 2013
Ended
23 September 2020
Enrollment
11 participants
Sites
1
Primary outcomes
Radiological assessment
Sponsor type
Academic / other
Results posted
No
Last update
21 October 2022

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The objectives of this study are to study the safety and effect of IRE as a treatment for inoperable hepatic and pancreatic malignancy.

Detailed description public domain (ClinicalTrials.gov)

Irreversible electroporation (IRE) is a form of non-thermal local ablation for solid tumors, it induces apoptosis of tumor cells by creating irreversible damage in the cell membrane using electric current. The use of thermal ablation for tumors adjacent to major blood vessels is not advisable because the "heat-sink effect" owing to blood vessels render the thermal treatment not effective. On the other hand, application of thermal ablation to a tumor adjacent to blood vessels or bile ducts will cause thermal damage to these structures. It has been shown in animal experiments that IRE is effective in causing cell death while blood vessels, bile ducts, and nerves in the vicinity are preserved. Early evidence of clinical studies has shown that IRE is a reasonably safe and effective treatment for pancreatic and hepatic tumors.